Full Name: Chlamydia Pneumoniae IgA ELISA Kit
Sample Type: Serum, Plasma
Sensitivity: diagn. 88.9%
The respiratory pathogen Chlamydia pneumoniae invades and replicates within epithelial cells, exhibiting a biphasic developmental cycle with infectious elementary bodies and larger replicative reticulate bodies. The elementary body functions as the infectious particle, equipped with a rigid cell wall and compact spore-like structure. Elementary bodies attach to and enter host cells, transitioning into reticulate bodies that proliferate via binary fission enclosed within a membrane-bound inclusion vacuole. Reticulate bodies can then revert back into elementary bodies that are released from the cell to transmit the infection.
C. pneumoniae possesses a cell wall containing LPS and outer membrane proteins that facilitate adhesion and entry into respiratory epithelial cells. Inside host cells, it circumvents immune detection and inhibition by blocking phagolysosome fusion. It is also able to adopt a persistent non-replicative state. Through its type III secretion system, C. pneumoniae injects effector proteins that manipulate host cell pathways to promote its own infection.
Although acute C. pneumoniae respiratory infections are generally mild, causing pharyngitis, sinusitis, or bronchitis, the bacterium has been associated with chronic diseases including asthma, COPD exacerbations, and community-acquired pneumonia. Seroprevalence studies show most people are infected at some point, and reinfection is common since natural immunity is short-lived.
Human Chlamydia pneumoniae IgA ELISA kit is designed for analysing in-vitro amounts of human IgA class antibodies to Chlamydia pneumoniae (Chlamydia pneumoniae-IgA) using plasma and serum samples. This assay has a minimum analytical sensitivity limit to a diagn. 88.9%.
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- Chlamydia pneumoniae Coated Microplate (IgA).
- Sample Diluent.
- Stop Solution.
- Washing Buffer (20x Conc.).
- Chlamydia pneumoniae anti-IgA Conjugate.
- TMB Substrate Solution.
- Positive Control.
- Cut-Off Control.
- Negative Control.
The minimum detection sensitivity level of human IgA class antibodies against Chlamydia pneumoniae using current Chlamydia pneumoniae IgA ELISA kit was to a diagn. 88.9%. The dynamic range for this assay is to a specific cut-off point.
– Cut-Off: 10 U
– Positive: > 11 U
– Equivocal: 9 – 11 U
– Negative: < 9 U
– Diagnostic Specificity: 98.98%
– Diagnostic Sensitivity: 91.89%
– Cross Reactivity: No false-positive results were revealed due to cross-reactions using a sample panel with antibody activities to potentially cross-reacting parameters.
– Interferences: Interferences with hemolytic, lipemic or icteric samples are not observed up to a concentration of 10 mg/ml hemoglobin, 5 mg/ml triglycerides and 0.5 mg/ml bilirubin.
- Close association of Chlamydia pneumoniae IgA seropositivity by ELISA with the presence of coronary artery stenosis in haemodialysis patients. Nephrol Dial Transplant. (2005) 20 (9): 1944-50. Nishimura M., et al.
- Comparison of individuals with and without specific IgA antibodies to Chlamydia pneumoniae: respiratory morbidity and the metabolic syndrome. Chest. (2002) 122 (5): 1587-93. Falck G., et al.
- Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J. (2002) 23 (5): 371-5. Danesh J., et al.
- Serological analysis of specific IgA to Chlamydia-pneumoniae: increased sensitivity of IgAantibody detection using prolonged incubation and high antigen concentration. APMIS. (2000) 108 (5): 357-62. Gnarpe J., et al.
- Chlamydia pneumoniae-IgA seropositivity and sudden sensorineural hearing loss. Otolaryngol Pol. (2004) 58 (3): 427-8. Dünne A.A., et al.
OTHER RELATED ELISA KITS
- Chlamydia Pneumoniae-IgG ELISA Kit
- Chlamydia Pneumoniae-IgM ELISA Kit
- Chlamydia Trachomatis-IgA ELISA Kit
Online Enquiry Form
"*" indicates required fields